Cargando…
Use of zoledronic acid in the treatment of Paget’s disease
This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bon...
Autores principales: | Seton, Margaret, Krane, Stephen M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376069/ https://www.ncbi.nlm.nih.gov/pubmed/18473015 |
Ejemplares similares
-
Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014) -
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
por: Cronin, Owen, et al.
Publicado: (2019) -
Response to Zoledronic Acid in Patients with Active Paget's Disease of Bone: A Retrospective Study
por: Durgia, Harsh, et al.
Publicado: (2019) -
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
por: Panteliou, Eleftheria, et al.
Publicado: (2011) -
Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62(P394L) mouse model of Paget's disease
por: Daroszewska, Anna, et al.
Publicado: (2018)